Current structure-based Methods for Designing non-nucleoside Reverse Transcriptase Inhibitors

Abstract

In 2019, structure-based methods continue to guide the design of novel antiretroviral therapies targeting HIV reverse transcriptase. This Review summarizes key findings from reverse transcriptase–non-nucleoside reverse transcriptase inhibitor analog crystal structure complexes reported from 2015 to 2019. Results from the literature and structure analysis have informed new ideas for structure-guided non-nucleoside reverse transcriptase inhibitor drug design.

Keywords:

• antiretroviral therapy
• computational chemistry
• crystal structures
• HIV
• molecular modeling
• NNRTIs
• non-nucleoside reverse transcriptase inhibitors
• RAMs
• resistance-associated mutations
• retrovirology
• reverse transcriptase
• RT
• structure-based drug design

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.